Straits Times Index
3,077.16 -6.92 (-0.22%) S&P 500
4,569.78 -24.85 (-0.54%) Dow
36,204.44 -41.06 (-0.11%) Nasdaq
14,185.49 -119.54 (-0.84%) Bitcoin USD
41,991.86 +192.23 (+0.46%) CMC Crypto 200
860.97 +2.26 (+0.26%)
LLY Jan 2025 320.000 call
| Previous close | 314.64 |
| Open | 314.64 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 320.00 |
| Expiry date | 2025-01-17 |
| Day's range | 314.64 - 314.64 |
| Contract range | N/A |
| Volume | |
| Open interest | 52 |
ReutersEli Lilly's obesity drug now available in U.S. pharmacies
The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates. Lilly's drug tirzepatide has been available as Mounjaro for type 2 diabetes since 2022 and had increasingly been used "off-label" for weight loss while the obesity approval was pending.
- Reuters
UPDATE 1-Eli Lilly's obesity drug now available in U.S. pharmacies
Eli Lilly's recently approved obesity drug Zepbound is now available in U.S. pharmacies and could be available to some insured customers at $550 per month or half of the list price, the U.S. drugmaker said on Tuesday. The company is making the weight-loss drug accessible to adults through its commercial savings card program, where people who are commercially insured with coverage may be eligible to pay as low as $25 for a 1-month or 3-month prescription. The drug was approved in November, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates.
PR NewswireZepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity
Eli Lilly and Company (NYSE: LLY) today announced that Zepbound™ (tirzepatide) injection is now available. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who are overweight (with a BMI of 27 kg/m2 or greater) and also have weight-related medical problems such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea or cardiovascular disease, to lose weight and keep it off. It should be used with a reduced-calorie diet and incre
